NCT05142709

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,197 (actual)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Detailed description

This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) patients who were treated with ICIs as 1st line treatment at approximately 26 institutions. The patients should have received at least 1 cycle of anti-PD-1 immunotherapy with or without radiotherapy. Based on these data, overall survival (OS), progression free survival (PFS) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.

Conditions

• Metastatic Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Anti-PD-1 Immune Checkpoint Inhibitors	used as 1st line treatment for metastatic ESCC.

Timeline

• Start date: 2021-10-31
• Primary completion: 2023-09-30
• Completion: 2025-12-31
• First posted: 2021-12-03
• Last updated: 2026-02-05

Locations

23 sites across 1 country: China